Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis

JAMA Neurology

Volumn 73, Issue 5, 2016, Pages 520-528

  Negrotto, Laura ^a   Farez, Mauricio F ^a   Correale, Jorge ^a  

^a FLENI   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ADIPONECTIN; ANTIHYPERTENSIVE AGENT; BETA INTERFERON; GADOLINIUM; GAMMA INTERFERON; GLATIRAMER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; LEPTIN; METFORMIN; MYELIN BASIC PROTEIN; NATALIZUMAB; PENTETIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TUMOR NECROSIS FACTOR; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ANTIINFLAMMATORY AGENT; CYTOKINE; MESSENGER RNA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY MASS; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE DURATION; DYSLIPIDEMIA; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; IMMUNOREGULATION; MALE; METABOLIC SYNDROME X; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WAIST CIRCUMFERENCE; BLOOD; BRAIN; COMPLICATION; DIAGNOSTIC IMAGING; DISABILITY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMAGE PROCESSING; METABOLISM; NONPARAMETRIC TEST; PATHOLOGY; TIME FACTOR;

ADIPOKINES; ANTI-INFLAMMATORY AGENTS; BRAIN; COHORT STUDIES; CYTOKINES; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LEPTIN; MAGNETIC RESONANCE IMAGING; MALE; METFORMIN; MULTIPLE SCLEROSIS; OBESITY; PPAR GAMMA; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES, REGULATORY; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 84966570157     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.4807     Document Type: Article

References (44)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-1517.
2. Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14 (4):406-419.
3. Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother. 2013;13(12)(suppl): 3-9.
4. Correale J, Gaitán MI. Multiple sclerosis and environmental factors. Acta Neurol Scand. 2015;132 (199):46-55.
5. International Multiple Sclerosis Genetics Consortium. Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. Am J Hum Genet. 2013; 92(6):854-865.
6. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347(12):911-920.
7. Melcon MO, Correale J, Melcon CM. Is it time for a new global classification of multiple sclerosis? J Neurol Sci. 2014;344(1-2):171-181.
8. Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2015;33(7): 673-689.
9. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1. Diabet Med. 1998;15(7): 539-553.
10. Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology. 2009;73(19):1543-1550.
11. Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014;13(9):981-1000.
12. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol. 2004;4(5):371-379.
13. Härle P, Straub RH. Leptin is a link between adipose tissue and inflammation. Ann N Y Acad Sci. 2006;1069:454-462.
14. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha. Science. 1993;259(5091):87-91.
15. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821-1830.
16. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis. Ann Neurol. 2011;69(2):292-302.
17. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444-1452.
18. Correale J, Rush C, Amengual A, Goicochea MT. Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-β. J Neuroimmunol. 2005;162(1-2):173-183.
19. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet. 2002;3(10):737-747.
20. Nath N, Khan M, Paintlia MK, Singh I, Hoda MN, Giri S. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis [published correction appears in J Immunol. 2009;183(5):3551]. J Immunol. 2009;182(12):8005-8014.
21. Paintlia AS, Paintlia MK, Mohan S, Singh AK, Singh I. AMP-activated protein kinase signaling protects oligodendrocytes that restore central nervous system functions in an experimental autoimmune encephalomyelitis model. Am J Pathol. 2013;183(2):526-541.
22. Kang KY, Kim YK, Yi H, et al. Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis. Int Immunopharmacol. 2013;16(1):85-92.
23. Koh SJ, Kim JM, Kim IK, Ko SH, Kim JS. Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer. J Gastroenterol Hepatol. 2014;29(3):502-510.
24. Feinstein DL, Galea E, Gavrilyuk V, et al. Peroxisome proliferator-activated receptor-γ agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol. 2002;51(6):694-702.
25. Gray E, Ginty M, Kemp K, Scolding N, Wilkins A. The PPAR-γ agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function. J Neuroinflammation. 2012;9:63.
26. Hucke S, Floßdorf J, Grützke B, et al. Licensing ofmyeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ. Brain. 2012;135 (pt 5):1586-1605.
27. Abella V, Scotece M, Conde J, et al. Adipokines, metabolic syndrome and rheumatic diseases. J Immunol Res. 2014;2014:343746.
28. Storer PD, Xu J, Chavis J, Drew PD. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes. J Neuroimmunol. 2005;161(1-2):113-122.
29. Matarese G, Carrieri PB, Montella S, De Rosa V, La Cava A. Leptin as ametabolic link to multiple sclerosis. Nat Rev Neurol. 2010;6(8):455-461.
30. Sanna V, Di Giacomo A, La Cava A, et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest. 2003;111(2):241-250.
31. Kraszula L, Jasińska A, Eusebio M, Kuna P, Głąbiński A, Pietruczuk M. Evaluation of the relationship between leptin, resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosis. Neurol Neurochir Pol. 2012;46(1): 22-28.
32. Evangelopoulos ME, Koutsis G, Markianos M. Serum leptin levels in treatment-naive patients with clinically isolated syndrome or relapsing-remitting multiple sclerosis. Autoimmune Dis. 2014;2014: 486282.
33. Messina S, Vargas-Lowy D, Musallam A, et al. Increased leptin and A-FABP levels in relapsing and progressive forms of MS. BMC Neurol. 2013;13:172.
34. Emamgholipour S, Eshaghi SM, Hossein-nezhad A, Mirzaei K, Maghbooli Z, Sahraian MA. Adipocytokine profile, cytokine levels and foxp3 expression in multiple sclerosis. PLoS One. 2013;8(10):e76555. doi:10.1371/journal.pone.0076555.
35. Piccio L, Cantoni C, Henderson JG, et al. Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis. Eur J Immunol. 2013;43(8):2089-2100.
36. Musabak U, Demirkaya S, Genç G, Ilikci RS, Odabasi Z. Serum adiponectin, TNF-α, IL-12p70, and IL-13 levels in multiple sclerosis and the effects of different therapy regimens. Neuroimmunomodulation. 2011;18(1):57-66.
37. Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, Heneka MT. Anti-inflammatory and antiproliferative actions of PPAR-γ agonists on T lymphocytes derived from MS patients. J Leukoc Biol. 2004;75(3):478-485.
38. Shukla DK, Kaiser CC, Stebbins GT, Feinstein DL. Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients. Neurosci Lett. 2010;472(3):153-156.
39. Kaiser CC, Shukla DK, Stebbins GT, et al. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol. 2009;211(1-2):124-130.
40. Wang H, Li T, Chen S, Gu Y, Ye S. Neutrophil extracellular trap mitochondrial DNA and its autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin. Arthritis Rheumatol. 2015;67(12):3190-3200.
41. Marder W, Khalatbari S, Myles JD, et al. The peroxisome proliferator activated receptor-γ pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis. J AmHeart Assoc. 2013;2(6): e000441.
42. Shafiq N, Malhotra S, Pandhi P, Gupta M, Kumar B, Sandhu K. Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6) [published correction appears in Int J Dermatol. 2005;44(7):622]. Int J Dermatol. 2005;44(4): 328-333.
43. Kleinewietfeld M, Hafler DA. Regulatory T cells in autoimmune neuroinflammation. Immunol Rev. 2014;259(1):231-244.
44. Wagner NM, Brandhorst G, Czepluch F, et al. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity (Silver Spring). 2013;21(3):461-468.